Acute Pulmonary Embolism Management Guidelines

Risk Stratification & Immediate Anticoagulation

• Hemodynamic status must be assessed first; it fully determines the therapeutic strategy for acute PE (Class I, Level B) 1.
• Patients with high or intermediate clinical probability should receive anticoagulation immediately, even while diagnostic work‑up is ongoing (Class I, Level A) [2][3]1.
• For high‑risk (massive) PE, unfractionated heparin (UFH) is given intravenously as an 80 U/kg bolus followed by 18 U/kg/h infusion, without waiting for imaging confirmation (Class I, Level B) 1.

Treatment of High‑Risk (Massive) PE

• Systemic thrombolysis is the first‑line therapy for high‑risk PE (Class I, Level B) 2.
• Approved thrombolytic regimens (Class I, Level B):
  
  • rt‑PA 100 mg over 2 h or 0.6 mg/kg over 15 min (max 50 mg) 4
  • Streptokinase 250 000 IU bolus over 30 min then 100 000 IU/h for 12–24 h 4
  • Urokinase 4 400 IU/kg bolus over 10 min then 4 400 IU/kg/h for 12–24 h 4
• If thrombolysis is contraindicated or fails, surgical embolectomy is recommended (Class I, Level C) [2][1].
• Percutaneous catheter‑directed therapy is an alternative to surgery (Class IIa, Level C) 2.
• Norepinephrine and/or dobutamine may be used for hemodynamic support (Class IIa, Level C) 2.
• Extracorporeal membrane oxygenation (ECMO) can be considered together with surgery or catheter therapy in refractory circulatory collapse or cardiac arrest (Class IIb, Level C) 2.

Treatment of Intermediate‑Risk or Low‑Risk PE

• When parenteral anticoagulation is chosen, low‑molecular‑weight heparin (LMWH) or fondaparinux is preferred over UFH (Class I, Level A) [2][3]1.
• Direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists (VKAs) in eligible patients (Class I, Level A) [2][3]1.
• DOACs are contraindicated in: severe renal impairment (CrCl < 30 mL/min), pregnancy or lactation, and antiphospholipid‑antibody syndrome (Class I, Level A) [2][3]1.
• If a VKA is used, it must be overlapped with parenteral anticoagulation until the INR reaches 2.5 (target 2.0–3.0) (Class I, Level A) [2][3].
• Routine primary thrombolysis is not recommended for intermediate‑ or low‑risk PE (Class III, Level B) [2][3].
• Rescue thrombolysis is advised for patients who develop hemodynamic deterioration (hypotension, shock, need for vasopressors) while on anticoagulation (Class I, Level B) [2][3].

Duration of Anticoagulation

• All patients with acute PE require at least 3 months of therapeutic anticoagulation (Class I, Level A) 1.
• Anticoagulation may be stopped after 3 months if the index PE was provoked by a transient/reversible risk factor (e.g., surgery, trauma, immobilization) (Class I, Level A) 1.
• Indefinite oral anticoagulation is recommended for:
  
  • Recurrent venous thromboembolism not related to a transient risk factor (Class I) 1
  • Antiphospholipid‑antibody syndrome (use VKA, not DOAC) (Class I) 1
• Patients on long‑term anticoagulation should have regular reassessment of drug tolerance, adherence, hepatic and renal function, and bleeding risk (Class I, Level A) 1.

Inferior Vena Cava (IVC) Filters

• Routine use of IVC filters is not recommended (Class III, Level A) [2][3]1.
• IVC filters may be considered in:
  
  • Acute PE with absolute contraindication to anticoagulation (Class IIa, Level C) [2][3]
  • Recurrent PE despite therapeutic anticoagulation (Class IIa, Level C) [2][3].

Early Discharge & Home Treatment

• Selected low‑risk PE patients may be discharged early and managed at home provided appropriate outpatient follow‑up and anticoagulation can be ensured (Class IIa, Level A) 2.

Common Pitfalls to Avoid

• Do not delay anticoagulation while awaiting diagnostic confirmation in patients with high or intermediate clinical probability (Class I, Level A) [2][3]1.
• Do not use DOACs in severe renal impairment, pregnancy, or antiphospholipid‑antibody syndrome; instead use UFH or LMWH followed by a VKA (Class I, Level A) [2][1].
• Do not give routine thrombolysis to intermediate‑risk PE; reserve it for hemodynamic deterioration (Class III, Level B) [2][3].

Pulmonary Embolism Treatment Guidelines

Introduction to Pulmonary Embolism Management

• The European Society of Cardiology recommends initiating anticoagulation immediately without delay in all patients with suspected pulmonary embolism (PE) while diagnostic workup is in progress, unless absolute contraindications exist 5, 6

Risk Stratification Framework

• The European Society of Cardiology suggests that risk stratification based on hemodynamic stability is the critical first step that determines treatment intensity 5, 6
• High-risk PE is characterized by hemodynamic instability, with systolic blood pressure less than 90 mmHg, need for vasopressors, or shock 5, 6, 7
• Intermediate-risk PE is defined as hemodynamically stable but with evidence of right ventricular dysfunction or myocardial injury 5, 6
• Low-risk PE is characterized by hemodynamic stability without right ventricular dysfunction 5, 6

Treatment Algorithm by Risk Category

High-Risk PE (Hemodynamically Unstable)

• Systemic thrombolytic therapy is the recommended first-line treatment for high-risk PE, with a Class I, Level B recommendation 5, 6
• Unfractionated heparin (UFH) with weight-adjusted bolus should be initiated immediately, with a Class I, Level C recommendation 5, 6
• Norepinephrine and/or dobutamine should be considered for hemodynamic support, with a Class IIa, Level C recommendation 5, 6
• Surgical pulmonary embolectomy is recommended if thrombolysis is contraindicated or fails, with a Class I, Level C recommendation 5, 6
• Percutaneous catheter-directed treatment should be considered as an alternative, with a Class IIa, Level C recommendation 5, 6

Intermediate-Risk and Low-Risk PE (Hemodynamically Stable)

• For parenteral anticoagulation, low molecular weight heparin (LMWH) or fondaparinux is recommended over unfractionated heparin (UFH), with a Class I, Level A recommendation 5, 6
• For oral anticoagulation, a direct oral anticoagulant (NOAC) is recommended in preference to a vitamin K antagonist (VKA), with a Class I, Level A recommendation 5, 6
• Dabigatran and edoxaban are specific NOAC options, with a recommendation based on 5, 6
• If VKA is used instead, overlap with parenteral anticoagulation until international normalized ratio (INR) reaches 2.5 (range 2.0-3.0), with a Class I, Level A recommendation 5, 6

Special Populations and Contraindications

• NOACs are contraindicated in severe renal impairment, pregnancy, and antiphospholipid syndrome, with a recommendation based on 5, 6, 8
• For antiphospholipid syndrome patients, continue VKA indefinitely, with a Class I recommendation 8
• For pregnant patients, use therapeutic fixed doses of LMWH based on early pregnancy weight, with a recommendation based on 8

Duration of Anticoagulation

• All patients require therapeutic anticoagulation for more than 3 months minimum, with a Class I recommendation 8
• Discontinue after 3 months if the first PE was secondary to a major transient/reversible risk factor, with a recommendation based on 8
• Continue indefinitely if there is recurrent venous thromboembolism (VTE) or antiphospholipid antibody syndrome, with a recommendation based on 8, 7

Inferior Vena Cava Filters

• IVC filters should be considered in acute PE with absolute contraindications to anticoagulation, with a Class IIa, Level C recommendation 5, 6
• Routine use of IVC filters is not recommended, with a Class III, Level A recommendation 5, 6, 8

Discharge Planning

• Carefully selected low-risk PE patients should be considered for early discharge and home treatment, with a Class IIa, Level A recommendation 5
• All patients should be routinely re-evaluated 3-6 months after acute PE to assess for chronic thromboembolic pulmonary hypertension and persistent symptoms, with a recommendation based on 9, 8